glucarpidase (voraxaze) Report issue

Biologics Recombinant protein Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Glucarpidase (Voraxaze) is a medication used for the treatment of elevated levels of methotrexate during treatment of cancer patients who have impaired kidney function. Glucarpidase is an enzyme that inactivates methotrexate rapidly after injection. Because this agent reduces systemic levels of methotrexate and could therefore interfere with efficacy, it is not recommended for use in patients with normal or only slightly impaired kidney function or in whom serum levels are normal. The main antidote for methotrexate overdoses prior to the approval of this drug were high doses of folinic acid. However, this agent was not always sufficient at preventing kidney failure due to methotrexate. Glucarpidase also degrades folinic acid so the two should not be used together.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$23697.3700 - $29795.1400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

carboxypeptidase g2 | carboxypeptidase-g2 | folate hydrolase g2 | glucarpidase | glutamate carboxypeptidase | pteroylmonoglutamic acid hydrolase g2 | voraxaze

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue